Multilevel models for estimating incremental net benefits in multinational studies
- 27 December 2006
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 16 (8) , 815-826
- https://doi.org/10.1002/hec.1198
Abstract
Multilevel models (MLMs) have been recommended for estimating incremental net benefits (INBs) in multicentre cost‐effectiveness analysis (CEA). However, these models have assumed that the INBs are exchangeable and that there is a common variance across all centres. This paper examines the plausibility of these assumptions by comparing various MLMs for estimating the mean INB in a multinational CEA. The results showed that the MLMs that assumed the INBs were exchangeable and had a common variance led to incorrect inferences. The MLMs that included covariates to allow for systematic differences across the centres, and estimated different variances in each centre, made more plausible assumptions, fitted the data better and led to more appropriate inferences. We conclude that the validity of assumptions underlying MLMs used in CEA need to be critically evaluated before reliable conclusions can be drawn. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- The Interpretation of Random-Effects Meta-Analysis in Decision ModelsMedical Decision Making, 2005
- Comparing costing results in across country economic evaluations: the use of technology specific purchasing power paritiesHealth Economics, 2004
- Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness dataHealth Economics, 2003
- Bayesian approaches to multiple sources of evidence and uncertainty in complex cost‐effectiveness modellingStatistics in Medicine, 2003
- Assessing the appropriateness of combining economic data from multinational clinical trialsStatistics in Medicine, 2003
- Bayesian Measures of Model Complexity and FitJournal of the Royal Statistical Society Series B: Statistical Methodology, 2002
- Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost‐effectiveness analysisHealth Economics, 2002
- A Comparison of the Costs and Survival of Hospital-Admitted Stroke Patients Across EuropeStroke, 2001
- Cross-national price differences for pharmaceuticals: how large, and why?Journal of Health Economics, 2000
- Cost Effectiveness of Clinical Diagnosis, Venography, and Noninvasive Testing in Patients with Symptomatic Deep-Vein ThrombosisNew England Journal of Medicine, 1981